Diclofenac - Zdorovye solution for injections of 25 mg/ml in ampoules of 3 ml, 5 pcs — Made in Ukraine — Free Delivery

Brand: Pharmaceutical company "Zdorovye"
Product Code: Diclofenac - Zdorovye
Availability: In Stock

$17.59

Description

Product description

Solution for injections "Diclofenac-Health" is used for the indications listed below.

When administered intramuscularly, it is prescribed for the treatment of:

inflammatory and degenerative forms of rheumatism, rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, spondyloarthritis, vertebral pain syndrome, non-articular rheumatism;
acute attacks of gout;
renal and biliary colic;
pain and swelling after injuries and operations;
severe migraine attacks.

The preparation, when administered as an intravenous infusion, is intended for the treatment or prevention of postoperative pain.

Composition

Active substance: diclofenac (1 ml of solution contains diclofenac sodium 25 mg).

Excipients: sodium metabisulfite (E 223), mannitol (E 421), propylene glycol, benzyl alcohol, sodium hydroxide, water for injections.

Contraindication

hypersensitivity to the components of the preparation, sodium metabisulfite;
history of bleeding or perforation of the gastrointestinal tract associated with previous treatment with nonsteroidal anti-inflammatory preparations (NSAIDs);
an active form of ulcer disease / bleeding or recurrent ulcer disease / bleeding in history (two or more separate episodes of established ulcer or bleeding);
III trimester of pregnancy;
like other NSAIDs, diclofenac is also contraindicated in patients in whom the use of ibuprofen, acetylsalicylic acid or other NSAIDs provokes attacks of bronchial asthma, angioedema, urticaria or acute rhinitis;
inflammatory bowel diseases (for example, Crohn's disease or ulcerative colitis);
liver failure;
renal failure (creatinine clearance <15 ml/minute/1.73 m2);
congestive heart failure (NYHA II-IV);
high risk of postoperative bleeding, blood clotting, hemostasis disorders, hematopoietic disorders or cerebrovascular bleeding;
treatment of perioperative pain during coronary bypass surgery (or the use of an artificial blood circulation device);
ischemic heart disease in patients who have angina pectoris and have suffered a myocardial infarction;
cerebrovascular diseases in patients who have suffered a stroke or have episodes of transient ischemic attacks;
diseases of peripheral arteries.

For intravenous use only:

simultaneous use of NSAIDs or anticoagulants (including large doses of heparin);
history of hemorrhagic diathesis, confirmed or suspected history of cerebrovascular bleeding;
operations associated with a high risk of bleeding;
history of bronchial asthma;
moderate or severe impairment of kidney function (serum creatinine > 160 μmol/l);
hypovolemia or dehydration due to any cause.

Application method

The dose should be selected individually, starting with the minimum effective dose, and the preparation should be used in the minimum effective dose for as short a period of time as possible, taking into account the task of treatment in each individual patient. Do not use for more than 2 days. If necessary, treatment can be continued with other medicinal forms of diclofenac.

One ampoule is intended for single use only. The solution should be used immediately after opening the ampoule. Any unused content must be disposed of.

Intramuscular injection

In order to prevent damage to nerves or other tissues at the injection site, the following rules should be followed. Such damage can lead to muscle weakness, muscle paralysis and paresthesia.

The dose is usually one ampoule of 75 mg per day by deep injection into the upper outer quadrant of the gluteal muscle. In severe cases (for example, colic), the daily dose can be increased to two injections of 75 mg, between which an interval of several hours must be observed (one injection in each buttock). Alternatively, one ampoule of 75 mg can be combined with other dosage forms of the preparation (for example, tablets, suppositories) up to a total maximum daily dose of 150 mg.

In the conditions of a migraine attack, clinical experience is limited to cases with the initial use of one ampoule of 75 mg, the dose should be administered as soon as possible after using suppositories of 100 mg on the same day (if necessary). The total daily dose should not exceed 175 mg on the first day. There are no available data on the use of the preparation for the treatment of migraine attacks for more than one day.

Intravenous infusions

The preparation should not be administered as a bolus injection. Immediately before starting the infusion, diclofenac, depending on its required duration, should be diluted in 100-500 ml of 0.9% sodium chloride solution or 5% glucose solution, buffered with sodium bicarbonate solution for injections (0.5 ml 8.4% solution or 1 ml of 4.2%, or the corresponding volume of another concentration), which is taken from a newly opened container, the content of one ampoule of the preparation. Only clear solutions can be used. If there are crystals or sediment in the solution, it cannot be used for infusion.

Two alternative preparation dosage regimens are recommended. For the treatment of moderate and severe postoperative pain, 75 mg should be administered continuously from 30 minutes to 2 hours. If necessary, the treatment can be repeated after a few hours, but the dose should not exceed 150 mg in any 24-hour period.

For the prevention of postoperative pain, a loading dose of 25-50 mg should be administered 15 minutes - 1 hour after surgery, after which a continuous infusion of approximately 5 mg / h should be used up to a maximum daily dose of 150 mg.

Features of application

pregnant

In the I and II trimesters of pregnancy, the preparation can be prescribed only if the expected benefit for the mother exceeds the potential risk for the fetus and only in the minimum effective dose. The duration of treatment should be as short as possible.

Like other nonsteroidal anti-inflammatory preparations, diclofenac penetrates into breast milk in small amounts. Thus, to avoid unwanted effects on the baby, the preparation should not be used during breastfeeding.

Like other nonsteroidal anti-inflammatory preparations, the preparation can affect a woman's fertility. The preparation is not recommended for women planning pregnancy. Women who have complications with fertilization, or those who have undergone an examination as a result of infertility, should stop using the preparation.

Children

The preparation in this dosage form should not be used by children.

Drivers

Patients who experience visual disturbances, dizziness, drowsiness or other nervous system disturbances during treatment with diclofenac should refrain from driving vehicles or other mechanisms.

Overdose

Symptoms

There is no typical clinical picture of the consequences of an overdose of diclofenac. Overdose may cause symptoms such as headache, nausea, vomiting, epigastric pain, gastrointestinal bleeding, diarrhea, dizziness, disorientation, agitation, coma, drowsiness, ringing in the ears, loss of consciousness, or convulsions. In case of severe poisoning, acute kidney failure and liver damage are possible.

Treatment

Within one hour after using a potentially toxic amount of the preparation inside, the possibility of using activated charcoal should be considered. In addition, in adults, gastric lavage should be considered for one hour after administration of a potentially toxic amount of the preparation. Diazepam should be administered intravenously in case of frequent or prolonged convulsions. Taking into account the clinical condition of the patient, other measures may be indicated. Treatment is symptomatic.

Side effects

The following side effects include those associated with the administration of diclofenacunatrium under conditions of short-term and long-term use.

From the blood and lymphatic system: thrombocytopenia, leukopenia, anemia (including hemolytic and aplastic), agranulocytosis.

From the side of the immune system: hypersensitivity, anaphylactic and anaphylactoid reactions (including arterial hypotension and shock), angioedema (including facial edema).

Mental disorders: disorientation, depression, insomnia, nightmares, irritability and other mental disorders.

From the side of the nervous system: headache, dizziness, drowsiness, fatigue, paresthesia, memory impairment, convulsions, anxiety, tremor, aseptic meningitis, taste disorder, stroke, confusion, hallucinations, sensitivity disorders, general malaise.

On the part of the organ of vision: vision disorder, blurred vision, diplopia, optic neuritis.

From the organs of hearing and labyrinth: vertigo, ringing in the ears, hearing impairment.

From the side of the heart: palpitations, chest pain, heart failure, myocardial infarction, Kounis syndrome.

From the side of the vascular system: arterial hypertension, arterial hypotension, vasculitis.

Respiratory, thoracic and mediastinal disorders: asthma (including shortness of breath), pneumonitis.

From the digestive system: nausea, vomiting, diarrhea, dyspepsia, abdominal pain, flatulence, gastritis, intestinal bleeding, vomiting with blood, hemorrhagic diarrhea, melena, ulcer of the stomach or intestines with bleeding, gastrointestinal stenosis with perforation (sometimes with a fatal outcome , especially in elderly patients), which can lead to peritonitis; colitis (including hemorrhagic colitis and exacerbation of ulcerative colitis or Crohn's disease), constipation, stomatitis (including ulcerative stomatitis), glossitis, disorders of the esophagus, membranous intestinal strictures, pancreatitis.

Hepatobiliary disorders: increase in the level of transaminases, hepatitis, jaundice, impaired liver function, acute hepatitis, hepatonecrosis, liver failure.

From the side of the skin and subcutaneous tissues: skin rashes, urticaria, bullous rashes, eczema, erythema, erythema multiforme, Stevens-Johnson syndrome, Lyell's syndrome, exfoliative dermatitis, hair loss, photosensitivity reaction, purpura, allergic purpura, itching.

From the kidneys and urinary tract: acute kidney injury (acute renal failure), hematuria, proteinuria, nephrotic syndrome, interstitial nephritis, renal papillary necrosis.

General disorders and disorders at the injection site: reaction at the injection site, pain, hardening, swelling, necrosis at the injection site, abscess at the injection site.

From the reproductive system and mammary glands: impotence.

There are data on the possibility of an increased risk of thrombotic complications (for example, myocardial infarction or stroke) associated with the use of diclofenac, in particular at high therapeutic doses (150 mg per day) and with long-term use.

Interaction

Do not mix the preparation with other solutions for injections.

Storage conditions

Store in the original packaging at a temperature not higher than 25 °C, in a place inaccessible to children.

Shelf life - 5 years.

0 reviews

There are no reviews for this product.